New framework shifts COPD care from symptom control to targeting disease drivers

For years, doctors have treated chronic obstructive pulmonary disease by managing symptoms and checking lung function. But a new guideline suggests a better path. It proposes shifting care from simple symptom control to modifying the actual disease process. This approach uses cellular phenotype classification to guide treatment. Doctors can now identify if a patient has neutrophilic, eosinophilic, lymphocytic, macrophage, or mixed granulocytic disease. Each type responds differently to specific therapies. The guideline highlights drugs like CXCR1/2 pathway inhibitors, neutrophil elastase inhibitors, anti-interleukin-5 biologics, anti-interleukin-13 biologics, and Th2 blockers. These targeted therapies aim to stop the specific biological mechanisms causing lung damage. This is a major step toward precision medicine for people with COPD. It moves away from a one-size-fits-all approach. The goal is to match the right drug to the right biological profile. This could lead to better outcomes for patients with this complex condition. However, substantial challenges remain in translating these cellular phenotypes into routine practice. We must work to make these advanced tools available to everyone who needs them.